Thermo Fisher Scientific (NYSE:TMO) Reaches New 1-Year High Following Earnings Beat

Thermo Fisher Scientific Inc. (NYSE:TMO)’s stock price reached a new 52-week high during trading on Thursday following a stronger than expected earnings report. The stock traded as high as $705.79 and last traded at $693.9840, with a volume of 4,049,061 shares changing hands. The stock had previously closed at $687.37.

The medical research company reported $6.68 earnings per share for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the prior year, the business earned $5.79 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 results exceeded expectations. Revenue increased 9% year over year to $12.14 billion, while adjusted EPS rose 15% to $6.68, surpassing the $6.40 consensus estimate. Organic growth reached 6%, supported by laboratory products and services, clinical research, bioproduction and improving end-market demand. Thermo Fisher Scientific Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its full-year outlook. Thermo Fisher lifted its 2026 organic revenue-growth expectation to 4% and increased full-year earnings and revenue guidance, indicating continued customer activity and improving demand. Operating margin expansion also contributed to profit growth. Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Analysts became more bullish. TD Cowen raised its price target to $810 and Stifel Nicolaus to $775, both with buy ratings; Robert W. Baird raised its target to $756 and maintained an outperform rating. TD Cowen price target
• Neutral Sentiment: Industry trends remain favorable. Research forecasts point to expanding peptide-synthesis and bioprocessing markets, including demand linked to GLP-1 drugs and biologics manufacturing. These opportunities benefit Thermo Fisher’s addressable markets but do not represent company-specific bookings or guidance.
• Negative Sentiment: The stock’s reaction has been cautious despite the beat. With shares near their 52-week high and trading at a premium earnings multiple, investors may have expected an even larger outlook increase. Unusual put-option activity also signals near-term hedging or bearish positioning.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $723.00 to $756.00 and gave the company an “outperform” rating in a research report on Thursday. BMO Capital Markets downgraded Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. Wells Fargo & Company lowered Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a research report on Wednesday, September 9th. Finally, Citigroup downgraded Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a research note on Wednesday, September 9th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $675.52.

Insider Buying and Selling

In other news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. The trade was a 43.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 420 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the sale, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 73,768 shares of company stock worth $44,122,820 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TMO. Tsfg LLC grew its position in shares of Thermo Fisher Scientific by 20.4% in the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 19 shares during the last quarter. Renasant Bank increased its stake in shares of Thermo Fisher Scientific by 1.0% in the second quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock worth $970,000 after purchasing an additional 20 shares during the period. Strengthening Families & Communities LLC lifted its position in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock worth $3,187,000 after purchasing an additional 21 shares during the last quarter. TCI Wealth Advisors Inc. lifted its position in shares of Thermo Fisher Scientific by 5.4% during the 1st quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock worth $212,000 after purchasing an additional 22 shares during the last quarter. Finally, Legacy Wealth Managment LLC ID boosted its stake in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

The stock has a market cap of $249.98 billion, a P/E ratio of 28.08, a P/E/G ratio of 2.89 and a beta of 0.87. The firm has a 50 day moving average of $644.01 and a two-hundred day moving average of $553.96. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.18 and a current ratio of 1.81.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.